Back to top

Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and ...

Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury | LCTX Stock News

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Lineage Cell Therapeutics, Inc. (LCTX)